Myocet Plus Endoxan for Older Patients With Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed metastatic breast adenocarcinoma * No more than one prior therapy regimen (other than hormonal therapy) for metastatic breast cancer is acceptable. * Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions) * Performance status (WHO) 0-2 * Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases) * Adequate renal function (serum creatinine \<1.5 times the upper normal limit) * Adequate cardiac function (LVEF within normal limits) * Adequate bone marrow function (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) * No radiation of measurable disease (except brain metastases) * No progressive brain metastases according to clinical or radiological criteria * No brain metastases without prior radiation therapy * Written informed consent Exclusion Criteria: * Active infection * History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) * Prior treatment with an anthracycline-containing regimen (as adjuvant therapy) during the previous 12 months period * Other invasive malignancy except non-melanoma skin cancer * Psychiatric illness or social situation that would preclude study compliance * Pregnant or lactating women